NCT03744676: A reported trial by Juno Therapeutics, a Subsidiary of Celgene
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03744676 |
|---|---|
| Title | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 29, 2018 |
| Completion date | Sept. 22, 2023 |
| Required reporting date | Sept. 21, 2024, midnight |
| Actual reporting date | Nov. 9, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |